Pacific Edge posts $14.5m loss as it awaits US Medicare decisions

Pacific Edge posts $14.5m loss as it awaits US Medicare decisions
Pacific Edge chief executive Peter Meintjes says as each day passes, he feels more confident about a favourable decision from Novitas. (Image: Supplied)
John Anthony
Dunedin-headquartered cancer diagnostics company Pacific Edge has posted a $14.5 million after-tax loss for the six months to September 30.The NZX and ASX-listed company said it was awaiting outcomes of several events that had the potential to renew growth in Cxbladder, its urine-based genomic biomarker test for the detection and surveillance of bladder cancer. The events include:Novitas, the Medicare Administrative Contractor (MAC) with responsibility for Pacific Edge’s US lab, making a favourable policy decision on a Local Coverage...

More Markets

Rocket Lab looks to raise up to US$500 million
Markets

Rocket Lab looks to raise up to US$500 million

The money will fund acquisitions and general corporate and working capital purposes.

The who’s who of NZME’s board hopefuls
Markets

The who’s who of NZME’s board hopefuls

Who are the players causing ripples in investor and media circles?

Duke pins recovery hopes on lower interest rates
Retail

Duke pins recovery hopes on lower interest rates

The Briscoe Group chief said he is ‘thrilled to bits’ with the full-year result.

NZSA waves red flags over NZME 'takeover by stealth'
Markets

NZSA waves red flags over NZME 'takeover by stealth'

Billionaire's bid to 'transfer control' of media company raises ire of NZSA.